1 Department of Medicine, Surgery, and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, Italy.
2 Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy.
3 Anatomy Patology, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To the editor
|Table 1. Patients’ characteristics.|
|Figure 1. Frequencies of immune cells in Hodgkin lymphoma (HL). (A) Percentage of immune cells at diagnosis were compared to those at interim PET (iPET; e.g., end of second ABVD), end of treatment (End), 3-month (3mo) and >1-year follow-up. Percentages of B regulatory cells (Breg), cytotoxic CD8+ T cells (CTL), Natural Killer cells (NK), T regulatory cells (Treg), NK T cells (NKT) are reported as mean+SD. The ratio between % of Treg and % of Breg is also shown. (B) Frequencies of Breg at the end of treatment between relapsed and no relapsed patients. (C) Using a % Breg < 0.4 as a cut-off, progression-free survival (PFS) between patients with Breg at the end of treatment lower or higher than the cut-off was compared. Data are reported as mean+SD. **, P < 0.05.|
Ethics Approval and Consent to Participate